Equity income managers warned that consumer stocks in alcohol and pharmaceuticals could disappoint investors in the coming years. “We’re reaching the desperation stage in pharmaceutical stocks,” one explained. This is partly due to pricing coming under heavy scrutiny and to the current US administration stance.


